Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC.NAVB · Entity 107761 | Director · CEO, COO & CFO | February 15, 2021 | February 17, 2021 |
| ProPhase Labs, Inc.PRPH · Entity 8699 | Director | January 01, 2024 | March 20, 2024 |
| WINDTREE THERAPEUTICS INC /DE/WINT · Entity 8761 | Director | August 13, 2024 | August 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NAVIDEA BIOPHARMACEUTICALS, INC.
Report date February 15, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2031-02-15 | Direct | 100,000 |
Reported balance
After 2021-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-15 · Grant · Acquired 100,000 · Balance 100,000 F1: Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of the first three anniversaries of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectHeld by 401(k) Plan | 10,600 |
Reported balance
Holding disclosure · report date 2021-02-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,600 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of the first three anniversaries of the date of grant.
ProPhase Labs, Inc.
Report date January 01, 2024 · Filed March 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2031-01-01 | Direct | 500,000 |
Reported balance
After 2024-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The option vests over a three year period, with 25% vesting on the date of grant and 25% vesting on each anniversary thereafter, subject to the Reporting Person's continued service through each vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a three year period, with 25% vesting on the date of grant and 25% vesting on each anniversary thereafter, subject to the Reporting Person's continued service through each vesting date
WINDTREE THERAPEUTICS INC /DE/
Report date August 13, 2024 · Filed August 14, 2024
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2024 Filed Mar 20, 2024 01:52 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 500,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-24-010575 · ownership.xml · derivative · entry 1 Latkin Jed · CIK 0001554593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-01-01 F1 · derivative.exercise_date: The option vests over a three year period, with 25% vesting on the date of grant and 25% vesting on each anniversary thereafter, subject to the Reporting Person's continued service through each vesting date Read SEC document |
| February 15, 2021 Filed Feb 17, 2021 16:08 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $2.56 | $100.00 |
DisclosureSEC source: 0001437749-21-003101 · rdgdoc.xml · derivative · entry 2 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-15 F1 · derivative.exercise_date: Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:13 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $4.70 | $100.00 |
DisclosureSEC source: 0001437749-20-018294 · rdgdoc.xml · derivative · entry 2 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-08-14 F2 · security: Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023. F2 · derivative.exercise_date: Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 21:13 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001437749-20-018294 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,997 F1 · security: Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:18 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock | 33,997 | $2.62 | $89,072.14 |
DisclosureSEC source: 0001437749-20-012480 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,997 F1 · date: Stock granted under the Amended and Restated 2014 Stock Incentive Plan in lieu of cash bonus. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 16:39 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 5,000 | $1.08 | $5,400.00 |
DisclosureSEC source: 0001437749-20-003172 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,950 Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 16:15 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $1.06 | $100.00 |
DisclosureSEC source: 0001437749-20-002040 · rdgdoc.xml · derivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,250 Underlying: Common Stock · 100,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: Stock options will vest one-third on each of the first three anniversaries of the date of grant. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:05 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 1,000 | $1.26 | $1,258.30 |
DisclosureSEC source: 0001437749-19-011608 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 Read SEC document |
| May 17, 2019 Filed May 17, 2019 16:05 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 1,000 | $1.46 | $1,462.90 |
DisclosureSEC source: 0001437749-19-010383 · rdgdoc.xml · nonDerivative · entry 2 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,950 Read SEC document |
| May 16, 2019 Filed May 17, 2019 16:05 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 1,500 | $1.45 | $2,180.40 |
DisclosureSEC source: 0001437749-19-010383 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,950 Read SEC document |
| May 15, 2019 Filed May 15, 2019 16:04 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 1,000 | $1.45 | $1,447.70 |
DisclosureSEC source: 0001437749-19-010054 · rdgdoc.xml · nonDerivative · entry 3 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 Read SEC document |
| May 14, 2019 Filed May 15, 2019 16:04 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 2,000 | $1.84 | $3,679.20 |
DisclosureSEC source: 0001437749-19-010054 · rdgdoc.xml · nonDerivative · entry 2 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,450 Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:04 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock | 2,400 | $1.91 | $4,594.56 |
DisclosureSEC source: 0001437749-19-010054 · rdgdoc.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,450 Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 18:22 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-002255 · rdgdoc.xml · derivative · entry 1 Latkin Jed · CIK 0001554593 · Director · CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,065,000 Underlying: Common Stock · 1,000,000 shares Expires 2029-02-07 F1 · derivative.exercise_price: 333,334 options with a strike price of $0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.50 per share; 333,333 options with a strike price of $0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.70 per share; and 333,333 options with a strike price of $0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share. F1 · derivative.exercise_date: 333,334 options with a strike price of $0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.50 per share; 333,333 options with a strike price of $0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.70 per share; and 333,333 options with a strike price of $0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share. Read SEC document |
| May 30, 2017 Filed May 31, 2017 17:28 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock, $.001 par value | 7,600 | $0.44 | $3,316.64 |
DisclosureSEC source: 0001654954-17-005235 · section16.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,159 Read SEC document |
| May 22, 2017 Filed May 23, 2017 17:40 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock, $.001 par value | 11,200 | $0.45 | $5,038.88 |
DisclosureSEC source: 0001654954-17-005032 · section16.xml · nonDerivative · entry 2 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,559 Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:40 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | PurchaseCommon Stock, $.001 par value | 14,159 | $0.45 | $6,387.12 |
DisclosureSEC source: 0001654954-17-005032 · section16.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,359 Read SEC document |
| May 18, 2017 Filed May 19, 2017 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock, $.001 par value | 3,900 | $0.45 | $1,753.44 |
DisclosureSEC source: 0001654954-17-004944 · section16.xml · nonDerivative · entry 2 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,200 Read SEC document |
| May 17, 2017 Filed May 19, 2017 16:10 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantCommon Stock, $.001 par value | 13,300 | $0.47 | $6,211.10 |
DisclosureSEC source: 0001654954-17-004944 · section16.xml · nonDerivative · entry 1 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,300 Read SEC document |
| May 04, 2017 Filed May 5, 2017 13:42 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-004110 · section16.xml · derivative · entry 1 Latkin Jed · CIK 0001554593 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,000 Underlying: Common Stock · 1,000,000 shares Expires 2027-05-04 F1 · derivative.exercise_price: 333,334 options with a strike price of $0.65 will be exercisable on or after 5/4/2017, so long as the closing market price of the underlying common stock equals or exceeds $0.85 per share; 333,333 options with a strike price of $0.75 will be exercisable on or after 12/31/2017, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share; and 333,333 options with a strike price of $1.00 will be exercisable on or after 12/31/2018, so long as the closing market price of the underlying common stock equals or exceeds $1.25 per share. F1 · derivative.exercise_date: 333,334 options with a strike price of $0.65 will be exercisable on or after 5/4/2017, so long as the closing market price of the underlying common stock equals or exceeds $0.85 per share; 333,333 options with a strike price of $0.75 will be exercisable on or after 12/31/2017, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share; and 333,333 options with a strike price of $1.00 will be exercisable on or after 12/31/2018, so long as the closing market price of the underlying common stock equals or exceeds $1.25 per share. Read SEC document |
| October 14, 2016 Filed Nov 1, 2016 10:29 UTC | NAVIDEA BIOPHARMACEUTICALS, INC. NAVB · Entity 107761 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001144204-16-130730 · v451739_4.xml · derivative · entry 1 Latkin Jed · CIK 0001554593 · Interim COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-10-14 F1 · derivative.exercise_date: Option vests to the extent of 10,000 shares each month over a period of two months commencing November 20, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.